Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: amphetamine Clear all
No Longer Available No phase listed Expanded access

A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

NCT04438512
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Midomafetamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Rockville, Maryland • Waynesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional Results available

Addressing Cognitive Fog in Long-COVID-19 Patients

NCT05597722
View directory record Official record
Conditions
Cognitive Impairment, Long COVID
Interventions
Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
21 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Stimulant Abuser Groups to Engage in 12-Step

NCT00573183
View directory record Official record
Conditions
Drug Abuse
Interventions
STAGE-12, Treatment as Usual
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Jacksonville, Florida • Kaneohe, Hawaii • Columbus, Ohio + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

NCT05379959
View directory record Official record
Conditions
Stimulant Use, MDMA ('Ecstasy'), Social Behavior, Motivation
Interventions
MDMA, Methamphetamine, placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

NCT00919867
View directory record Official record
Conditions
Healthy
Interventions
SPD503, VYVANSE, SPD503 and VYVANSE
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Early Phase 1 Interventional

MDMA-assisted Therapy for Fibromyalgia

NCT06066853
View directory record Official record
Conditions
Fibromyalgia
Interventions
MDMA
Drug
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD

NCT04264026
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Combat Stress Disorders
Interventions
3,4-methylenedioxymethamphetamine
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 2 Interventional

Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)

NCT00514202
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Placebo, Dextroamphetamine SR
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of MDMA on Social and Emotional Processing

NCT01849419
View directory record Official record
Conditions
Drug Addiction
Interventions
Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 3 Interventional Results available

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

NCT01738698
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 40mg, SPD489 100mg, SPD489 160mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tolerability of MDMA in Schizophrenia

NCT05770375
View directory record Official record
Conditions
Schizophrenia
Interventions
MDMA 40mg, MDMA 80mg, MDMA 120mg
Drug
Lead sponsor
Anya Bershad, MD, PhD
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional Results available

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds

NCT04095104
View directory record Official record
Conditions
Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
Interventions
Phentermine, Immediate Release Topiramate, Placebo for Phentermine, Placebo for Immediate Release Topiramate
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 24 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

Dextroamphetamine-Cocaine Behavioral Intervention - 5

NCT00000308
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Dextroamphetamine, D-amphetamine, placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of MDMA on Startle Response

NCT03181763
View directory record Official record
Conditions
Startle Response
Interventions
Placebo, Midomafetamine, Acoustic startle
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Caffeine and Cocaine

NCT00733993
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Caffeine 150 MG, Placebo, Amphetamine, Caffeine 300 MG
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 1 Interventional

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence

NCT01490216
View directory record Official record
Conditions
Cocaine Dependence
Interventions
lisdexamfetamine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 6:50 AM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 21, 2026, 6:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

NCT00746733
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lisdexamfetamine Dimesylate, Adderall XR (mixed salts amphetamine)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 6:50 AM EDT